Retrophin, Inc. (RTRX) Shares Sold by ProShare Advisors LLC
ProShare Advisors LLC lessened its stake in Retrophin, Inc. (NASDAQ:RTRX) by 5.5% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 22,972 shares of the biopharmaceutical company’s stock after selling 1,335 shares during the quarter. ProShare Advisors LLC owned 0.06% of Retrophin worth $445,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds also recently made changes to their positions in RTRX. SG Americas Securities LLC increased its holdings in shares of Retrophin by 1.8% in the 2nd quarter. SG Americas Securities LLC now owns 8,167 shares of the biopharmaceutical company’s stock valued at $158,000 after purchasing an additional 146 shares in the last quarter. Legal & General Group Plc increased its holdings in shares of Retrophin by 4.3% in the 2nd quarter. Legal & General Group Plc now owns 8,664 shares of the biopharmaceutical company’s stock valued at $168,000 after purchasing an additional 355 shares in the last quarter. Weiss Multi Strategy Advisers LLC purchased a new position in shares of Retrophin in the 1st quarter valued at about $185,000. Dynamic Technology Lab Private Ltd purchased a new position in shares of Retrophin in the 1st quarter valued at about $219,000. Finally, Fox Run Management L.L.C. purchased a new position in shares of Retrophin in the 2nd quarter valued at about $246,000.
A number of equities analysts have recently issued reports on RTRX shares. ValuEngine upgraded shares of Retrophin from a “sell” rating to a “hold” rating in a report on Monday, July 17th. BidaskClub upgraded shares of Retrophin from a “buy” rating to a “strong-buy” rating in a report on Thursday, August 24th. One investment analyst has rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the stock. The company has an average rating of “Buy” and an average target price of $36.50.
In other Retrophin news, COO Neil F. Mcfarlane sold 1,378 shares of the company’s stock in a transaction dated Wednesday, August 16th. The shares were sold at an average price of $22.50, for a total value of $31,005.00. Following the completion of the sale, the chief operating officer now directly owns 13,622 shares of the company’s stock, valued at approximately $306,495. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 2.41% of the stock is currently owned by corporate insiders.
ILLEGAL ACTIVITY WARNING: This news story was reported by Watch List News and is the sole property of of Watch List News. If you are accessing this news story on another publication, it was copied illegally and reposted in violation of international trademark and copyright laws. The legal version of this news story can be read at https://www.watchlistnews.com/retrophin-inc-rtrx-shares-sold-by-proshare-advisors-llc/1614586.html.
Retrophin, Inc. (NASDAQ RTRX) opened at 24.72 on Friday. The stock’s market capitalization is $948.88 million. Retrophin, Inc. has a 12-month low of $15.55 and a 12-month high of $25.44. The firm’s 50-day moving average is $23.99 and its 200 day moving average is $20.09.
Retrophin (NASDAQ:RTRX) last issued its quarterly earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.24) by ($0.10). Retrophin had a negative net margin of 48.74% and a negative return on equity of 7.31%. The business had revenue of $38.80 million during the quarter, compared to analyst estimates of $37.36 million. During the same period in the previous year, the company posted $0.07 earnings per share. Retrophin’s revenue was up 16.5% compared to the same quarter last year. Equities research analysts anticipate that Retrophin, Inc. will post ($1.13) earnings per share for the current year.
Retrophin, Inc is a biopharmaceutical company. The Company is focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. The Company sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin).
Receive News & Ratings for Retrophin Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.